Ye Hongying, Liao Weijie, Pan Jiongli, Shi Yin, Wang Qingqing
Institute of Immunology, Zhejiang University School of Medicine, Hangzhou 310058, China.
The Key Laboratory for Immunity and Inflammatory Diseases of Zhejiang Province, Hangzhou 310058, China.
J Zhejiang Univ Sci B. 2025 Mar 13;26(3):203-226. doi: 10.1631/jzus.B2300492.
Dysfunction of anti-tumor immune responses is crucial for cancer progression. Immune checkpoint blockade (ICB), which can potentiate T cell responses, is an effective strategy for the normalization of host anti-tumor immunity. In recent years, immune checkpoints, expressed on both tumor cells and immune cells, have been identified; some of them have exhibited potential druggability and have been approved by the US Food and Drug Administration (FDA) for clinical treatment. However, limited responses and immune-related adverse events (irAEs) cannot be ignored. This review outlines the development and applications of ICBs, potential strategies for overcoming resistance, and future directions for ICB-based cancer immunotherapy.
抗肿瘤免疫反应功能障碍对癌症进展至关重要。免疫检查点阻断（ICB）可增强T细胞反应，是使宿主抗肿瘤免疫正常化的有效策略。近年来，已在肿瘤细胞和免疫细胞上均有表达的免疫检查点被发现；其中一些已显示出潜在的可成药性，并已获得美国食品药品监督管理局（FDA）批准用于临床治疗。然而，有限的反应和免疫相关不良事件（irAEs）不容忽视。本综述概述了ICB的发展与应用、克服耐药性的潜在策略以及基于ICB的癌症免疫治疗的未来方向。
